#746: Notice from Microwave News
From Louis Slesin, Editor of Microwave news:
It’s become axiomatic that wide acceptance of non-thermal effects will come from developing biomedical therapies rather than from studying potential hazards. The health effects work is mostly sponsored by those who don’t want to find any. And they usually don’t (cf: the USAF, EPRI, CTIA, FGF, MMF etc.) So no one should be surprised that the latest advance comes from a small high-tech Israeli company, NovoCure, which is looking for innovative ways to treat cancer. It’s a breakthrough –most likely a major
NovoCure uses weak 100-200 kHz electric fields –the company calls them tumor treating fields or TTFields– to stunt the growth of cancer cells, either by slowing down their proliferation or by killing them off entirely. The company has now demonstrated this in four different cancer cell lines. Even more impressive is that tumor growth has been curtailed in mice, rats and, in a small pilot project, ten human patients with recurrent brain tumors (glioblastoma).
…. [continues on the Microwave News website]
Read the rest of our latest post on the Microwave News Web site,
Louis Slesin, PhD
Editor, Microwave News
A Report on Non-Ionizing Radiation
Phone: +1 (212) 517-2800; Fax: +1 (212) 734-0316
E-mail: ; Internet:
Mail: 155 East 77th Street, Suite 3D
New York, NY 10021, U.S.A.
P.S. Access to all the information on our Web site is freely available to
all. Please help support Microwave News. Please send us a contribution so
we can stay on the Web.
P.P.S. We hate spam too. If you don’t want to continue receiving these
updates, just send a message to firstname.lastname@example.org and we will
immediately remove you from our mailing list.
P.P.P.S. For those of you who receive this indirectly and wish to sign
up for our e-mails, please go to,
Also note that if you have spam blockers that might bounce our e-mails,
please make sure you put us in your address book. When an e-mail is
returned to us, we automatically delete the address from our mailing list.